Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
NOVN - Novan Inc
$1.34
-0.02(-1.10%)7:47:42 PM 1/22/2021
Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, a topical anti-viral product candidate. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was founded in 2006 and is headquartered in Morrisville, North Carolina.
Stock Chart

Summary:

  • RSI is at a high level of 72. A high level of RSI indicates the stock is overbought.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    01/21/2021NOVN
    NOVN: B-SIMPLE4: 90% Enrollment

    By John Vandermosten, CFA NASDAQ:NOVN READ THE LATEST NOVN RESEARCH REPORT Novan, Inc. (NASDAQ:NOVN) announced on January 19, 2021 that it had achieved 90% enrollment for its pivotal B-SIMPLE4 trial indicating 765 patients have been added. The trial is targeting enrollment of 850 patients across 55 clinical sites. Based on our read and the general trend in clinical trial enrollment, the

    01/19/2021NOVN
    Novan Provides Enrollment Update and Announces New Corporate Headquarters

    – B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to support various cGMP activities, including research and development and small-scale manufacturing capabilities – MORRISVILLE, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today provided an update that enrollment for its B-SIMPLE4 pivotal Phase 3 study ev...

    01/13/2021NOVN
    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Novan, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Novan, Inc. (NASDAQ: NOVN).

    01/8/2021NOVN
    Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

    MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat during the January 11th-14th H.C. Wainwright BioConnect 2021 Virtual Conference. A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 11, 2021, at 6:00 AM ET for those registered for the event and accessible on the...

    12/21/2020NOVN
    Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program

    – Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing – – Company targets initiating preclinical Investigational New Drug (IND) enabling studies in Q1 2021 – MORRISVILLE, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a Master Services Agreement (MSA) with Catalent, which will include support of chemistry, manufacturing and control (CMC) activitie...

    12/15/2020NOVN
    Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

    – Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment –MORRISVILLE, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 cli...

    12/3/2020NOVN
    Glaxo downgraded to neutral at UBS, which says European pharma 'cheap but not a bargain'

    GlaxoSmithKline was downgraded to neutral from buy at UBS, which said the European pharma sector is cheap -- trading at a double-digit discount to the market on forward price-to-earnings -- but not a bargain, since earnings per share are seen growing 8% next year vs. about 30% for the broader market. On Glaxo in particular, UBS said investors will gravitate toward a sum-of-the-parts valuation until things are clearer on the separation of its consumer health joint venture with Pfizer . UBS said ...

    11/10/2020NOVN
    NOVN: Molluscum Phase III 30% Enrolled

    By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Third Quarter 2020 Operational and Financial Results On October 30, 2020 Novan Inc. (NASDAQ:NOVN) reported third quarter financial results concurrent with the filing of its third quarter 10-Q updating investors on financial and operational results. Novan reported revenues of $1.3 million for the period and net loss of ($8.4)

    11/4/2020NOVN
    Novan Receives Approval to Transfer to Nasdaq Capital Market

    – Trading on Nasdaq Capital Market is expected to begin on November 5, 2020 – – Company receives additional 180-day grace period, until May 3, 2021, to satisfy the $1.00 bid price requirement to maintain Nasdaq listing – MORRISVILLE, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that on November 3, 2020, the Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) approved the Company's request to transfer its l...